A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples